Dr. Ming-Hsi Huang is an Investigator at the National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Taiwan. His major research interest at NHRI has been focused on the development of novel delivery vehicles for generating vaccine-induced long-term immunity as well as immunoregulatory agents for manipulating effective/harmful immune responses. His research group was the pioneer who engineers amphiphilic bioresorbable polymers as emulsifiers to bring on novel biomimetic vesicles in the pursuit of innovative vaccine design against emerging infectious diseases, in particular influenza-associated illness, hand-foot-mouth disease and coronavirus disease (COVID-19). During the past few years, he aimed to launch a mechanistic study on how colloidal vesicles interacting with immune cells and progressively elucidate the role of manufacturing process as well as each ingredient linking with vaccine immunogenicity. He also extends these aspects to optimize an appropriate vaccination route, such as subcutaneous, intramuscular or mucosal administration. These features are of great interest for further investigations on sustained delivery for cancer immunotherapy.
Dr. Ming-Hsi Huang is an Investigator at the National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Taiwan. His major research interest at NHRI has been focused on the development of novel delivery vehicles for generating vaccine-induced long-term immunity as well as immunoregulatory agents for manipulating effective/harmful immune responses. His research group was the pioneer who engineers amphiphilic bioresorbable polymers as emulsifiers to bring on novel biomimetic vesicles in the pursuit of innovative vaccine design against emerging infectious diseases, in particular influenza-associated illness, hand-foot-mouth disease and coronavirus disease (COVID-19). During the past few years, he aimed to launch a mechanistic study on how colloidal vesicles interacting with immune cells and progressively elucidate the role of manufacturing process as well as each ingredient linking with vaccine immunogenicity. He also extends these aspects to optimize an appropriate vaccination route, such as subcutaneous, intramuscular or mucosal administration. These features are of great interest for further investigations on sustained delivery for cancer immunotherapy.